EN   EN 
 
 
 EUROPEAN  
COMMISSION   
Brussels, XXX   
[…](2019) XXX  draft  
ANNEX  
 
ANNEX  
to the  
Commission Delegated Regulation (EU) ../..  
of XXX amending for the purposes of its adaptation to technical and scientific progress, 
Regulation (EC) No 1272/2008 of the European Parliament and of the Council on 
classification, labelling and packaging of substances and mixtures    
EN 5  EN ANNEX  
 
Annex VI to Regulation (EC) No 1272/2008 is amended as follows:  
(1) Part 1  is amended as follows:  
In point 1.3.1.1, the following notes J, K, L, M, N, P and R are amended as follows: :  
‘Note J:  
The harmonised classification as a carcinogen or mutagen applies unless it can be shown that the substance contains less than  0,1 % w/w benzene 
(EINECS No 200 -753-7), in which case a classification in accordance with Title 2 shall be performed also for these hazard classes. ’ 
‘Note K:  
The harmonised classification as a carcinogen or mutagen applies unless it can be shown that the substance contains less than  0,1 % w/w 1,3 - 
butadiene (EINECS No 203 -450-8), in which case a classification in accordance with Title 2 shall be performed also for these hazard classes. If 
the substance is not classified as a carcinogen or mutagen, at least the precautionary state ments (P1 02-)P210 -P403  should apply. ’ 
‘Note L:  
The harmonised classification as a carcinogen applies unless it can be shown that the substance contains less than 3% DMSO ex tract as measured 
by IP 346 (‘Determination of polycyclic aromatics in unused lubricating bas e oils and asphaltene free petroleum fractions – Dimethyl sulphoxide 
extraction refractive index method’, Institute of Petroleum, London), in which case a classification in accordance with Title  2 shall be performed 
also for these hazard classes. ’ 
‘Note M:  
The harmonised classification as a carcinogen applies unless it can be shown that the substance contains less than 0,005 % w/ w benzo[a] -pyrene 
(EINECS No 200 -028-5), in which case a classification in accordance with Title 2 shall be performed also for the se hazard classes. ’  
‘Note N :  
The harmonised classification as a carcinogen applies unless the full refining history is known and it can be shown that the substance from which 
it is produced is not a carcinogen, in which case a classification in accordance with Title 2 shall be performed also for these hazard classes. ’ 
 
  
EN 6  EN  
‘Note P:  
The harmonised classification as a carcinogen or mutagen applies unless it can be shown that the substance contains less than  0,1 % w/w benzene 
(EINECS No 200 -753-7), in  which case a classification in accordance with Title 2 shall be performed also for these hazard classes. When the 
substance is not classified as a carcinogen or mutagen at least the precautionary statements (P102 -)P260 -P262 -P301 + P310 -P331 should apply. ’ 
‘Note R: 
The classification as a carcinogen   need not apply to fibres with a Length Weighted Geometric Mean Di ameter (LWGMD) minus two 
standard geometric errors greater than 6 μm, as measured in accordance with Part A of the Annex to Commission Regulation  (EC) No 440/2008 .’ 
 
(2) In Part 3, Table 3 is amended as follows :  
 
(a) The following entries are inserted:  
Index No  
 Chemical name  EC No  CAS No  Classification  Labelling  Specific Conc. 
Limits, M -
factors and 
ATE  Note
s 
Hazard Class 
and Category 
Code(s)  Hazard 
statement 
Code(s)  Pictogram, 
Signal 
Word   Code(s)  Hazard 
statement 
Code(s)  Suppl. 
Hazard 
statement 
Code(s)  
‘007-030-00-3 nitric acid …% [C ≤ 70 %]  231-714-2 7697 -37-2 Ox. Liq. 3   
Acute Tox. 3   
Skin Corr. 1A  H272  
H331  
H314  GHS03  
GHS06  
GHS05  
Dgr H272  
H331  
H314  EUH071  Ox. Liq. 3; 
H272: C ≥ 65 %  
inhalation: ATE 
= 2.65  mg/L  
(vapour s)  
Skin Corr. 1A; 
H314: C ≥ 20 %  
Skin Corr. 1B; 
H314: 5 % ≤ C 
<¶20 % ’ B 
‘014-048-00-5 silicon carbide fibres (with diameter < 3 
µm, length > 5 µm and aspect ratio ≥ 3:1)  206-991-8 409-21-2 
308076 -74-6 Carc. 1B  H350i  GHS08  
Dgr H350i ’      
EN 7  EN                                                  
1 RAC recommended a Note to be included which defines the dimension of the granules. Particle size ranges have been included below the chemical name for 
information.  ‘014-049-00-0 trimethoxyvinylsilane; 
trimethoxy(vinyl)silane  220-449-8 2768 -02-7 Skin Sens. 1B  H317  GHS07  
Wng  H317 ’     
‘014-050-00-6 tris(2 -methoxyethoxy)vinylsilane;  
6-(2-methoxyethoxy) -6-vinyl -2,5,7,10 -
tetraoxa -6-silaundecane  213-934-0 1067 -53-4 Repr. 1B  H360FD  GHS08  
Dgr H360FD ’    
‘016-098-00-3 dimethyl disulphide  210-871-0 624-92-0 Flam. Liq. 2  
Acute Tox. 3  
Acute Tox. 3  
STOT SE 3  
STOT SE 1  
Eye Irrit. 2 
Skin Sens. 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H225  
H331  
H301  
H370 (upper 
respiratory 
tract, 
inhalation)  
H319  
H317  
H400  
H410  GHS02  
GHS06  
GHS09  
Dgr H225  
H331  
H301  
H336  
H370 (upper 
respiratory 
tract, 
inhalation)  
H319  
H317  
H410   inhalation: ATE  
= 5 mg/L 
(vapour s) 
oral: ATE = 190 
mg/kg bw ¶ 
 
M=1  
M=10 ’  
‘029-024-00-X granulated copper ; 
[particle length: from  0.9 mm to  6.0 mm ; 
particle  width: from 0.494 to 0.949 mm ]  231-159-6 7440 -50-8 Aquatic Chronic 
2 H411  GHS09  H411    Note1’ 
‘029-025-00-5 bis(N-hydroxy -N-
nitrosocyclohexylaminato -O,O')copper;  
bis(N-cyclohexyl -diazenium -dioxy) -
copper;  
[Cu-HDO]  239-703-4 312600 -89-8 
15627 -09-5 Flam. Sol. 1  
Acute Tox. 4  
STOT RE 2  
Eye Dam. 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H228  
H302  
H373 (liver)  
H318  
H400  
H410  GHS02  
GHS07  
GHS08  
GHS05  
GHS09  
Dgr H228  
H302  
H373 (liver)  
H318  
H410   oral: ATE = 360  
mg/kg bw ¶ 
M=1  
M=1 ’  
‘050-031-00-9 dioctyltin dilaurate; [1]  
stannane, dioctyl -, bis(coco acyloxy) 
derivs. [2]  222-883-3 [1] 
293-901-5 [2]  3648 -18-8 [1] 
91648 -39-4 [2]  Repr. 1B  
STOT RE 1  H360D  
H372 (immune 
system)  GHS08  
Dgr H360D  
H372 
(immune 
system) ’    
‘601-092-00-0 dibenzo[ def,p]chrysene;  
dibenzo[ a,l]pyrene  205-886-4 191-30-0 Carc. 1B  
Muta. 2  H350  
H341  GHS08  
Dgr H350  
H341   Carc. 1B; H350: 
C ≥ 0,001 % ’   
EN 8  EN ‘603-237-00-3 ipconazole (ISO ); 
(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-
chlorobenzyl) -5-isopropyl -1-(1H-1,2,4 -
triazol -1-ylmethyl)cyclopentanol  
 - 125225 -28-7 
115850 -69-6 
115937 -89-8 Repr. 1B  
Acute Tox. 4  
STOT RE 2  
Aquatic Chronic 
1 H360D  
H302  
H373 (eyes, 
skin, liver)  
H410  GHS08  
GHS07  
GHS09  
Dgr H360D  
H302  
H373 (eyes, 
skin, liver)  
H410   oral: ATE = 500 
mg/kg bw   
M=100 ’  
‘603-238-00-9 bis(2 -(2-methoxyethoxy)ethyl)ether; 
tetraglyme  205-594-7 143-24-8 Repr. 1B  H360FD  GHS08  
Dgr H360FD ’    
‘603-239-00-4 paclobutrazol (ISO);  
(2RS,3RS)-1-(4-chlorophenyl) -4,4-
dimethyl -2-(1H-1,2,4 -triazol -1-
yl)pentan -3-ol - 76738 -62-0 Repr. 2  
Acute Tox. 4  
Acute Tox. 4  
Eye Irrit. 2  
Aquatic Acute 1  
Aquatic Chronic 
1 H361d  
H332  
H302  
H319  
H400  
H410  GHS08  
GHS07  
GHS09  
Wng  H361d  
H332  
H302  
H319  
H410   inhalation:  ATE 
= 3.13 mg/L 
(dust s and 
mists) 
oral: ATE = 490 
mg/kg bw  
M=10  
M=10 ’  
‘603-240-00-X 2,2-bis(bromomethyl)propane -1,3-diol 221-967-7 3296 -90-0 Carc. 1B  
Muta. 1B  H350  
H340  GHS08  
Dgr H350  
H340 ’    
‘603-241-00-5 geraniol;  
(2E)-3,7-dimethylocta -2,6-dien-1-ol 203-377-1 106-24-1 Skin Sens. 1  H317  GHS07  
Wng  H317 ’    
‘605-041-00-3 2-(4-tert-butylbenzyl)propionaldehyde  201-289-8 80-54-6 Repr. 1B  H360Fd  GHS08  
¶Dgr H360Fd ’    
‘607-738-00-8 MCPA -thioethyl (ISO);  
S-ethyl (4 -chloro -2-
methylphenoxy)ethanethioate; S-ethyl 4 -
chloro -o-tolyloxythioacetate  246-831-4 25319 -90-8 Acute Tox. 4  
STOT RE. 2  
Aquatic Acute 1 
Aquatic Chronic 
1 H302  
H373 (liver)  
H400  
H410  GHS07  
GHS08  
GHS09  
Wng  H302  
H373 (liver)  
H410   oral: ATE = 450 
mg/kg bw  
 
M=10  
M=10 ’  
‘607-740-00-9 diisooctyl phthalate  248-523-5 27554 -26-3 Repr. 1B  H360FD  GHS08  
Dgr H360FD ’    
‘607-741-00-4 4-{[(6-chloropyridin -3-yl)methyl](2,2 -
difluoroethyl)amino}furan -2(5H)-one; 
flupyradifurone  - 951659 -40-8 Acute Tox. 4  
STOT RE  2 
Aquatic Acute 1  
Aquatic Chronic 
1 H302  
H373 (muscle)  
H400  
H410  GHS07  
GHS08  
GHS09  
Wng  H302  
H373 
(muscle)  
H410   oral: ATE = 500 
mg/kg bw  
M=10  
M=10 ’  
‘607-742-00-X thiencarbazone -methyl (ISO);  
methyl 4 -[(4,5 -dihydro -3-methoxy -4-
methyl -5-oxo-1H-1,2,4 -triazol -1-
yl)carbonylsulfamoyl] -5- 
methylthiophene -3-carboxylate  - 317815 -83-1 Aquatic Acute 1  
Aquatic Chronic 
1 H400  
H410  GHS09  
Wng  H410   M=1000  
M=1000 ’   
EN 9  EN ‘607-743-00-5 L-(+)-lactic acid;  
(2S)-2-hydroxypropanoic acid  201-196-2 79-33-4 Skin Corr. 1C  
Eye Dam. 1  H314  
H318  GHS05  
Dgr H314  EUH071 ’   
‘607-744-00-0 2-methoxyethyl acrylate  221-499-3 3121 -61-7 Flam. Liq. 3  
Muta. 2  
Repr. 1B  
Acute Tox. 3  
Acute Tox. 4  
Skin Corr. 1C  
Eye Dam. 1  
Skin Sens. 1  H226  
H341  
H360FD  
H331  
H302  
H314  
H318  
H317  GHS02  
GHS05  
GHS06  
GHS08  
Dgr H226  
H341  
H360FD  
H331  
H302  
H314  
H317  EUH071  inhalation: ATE 
= 2.7 mg/L  
(vapour s) 
oral: ATE = 404  
mg/kg bw ’  
‘607-745-00-6 glyoxylic acid …%  206-058-5 298-12-4 Eye Dam. 1  
Skin Sens. 1B  H318  
H317  GHS05  
GHS07  
Dgr H318  
H317    B’ 
‘607-746-00-1 sodium N-(hydroxymethyl)glycinate;  
[formaldehyde released from sodium N-
(hydroxymethyl)glycinate]  274-357-8 70161 -44-3 Carc. 1B  
Muta. 2  
Acute Tox. 4  
Acute Tox. 4  
STOT SE 3  
Skin Irrit. 2 
Eye Irrit. 2  
Skin Sens. 1  H350  
H341  
H332  
H302  
H335  
H315  
H319  
H317  GHS08  
GHS07  
Dgr H350  
H341  
H332  
H302  
H335  
H315  
H319  
H317   inhalation: ATE 
= 3 mg/L (dust s 
and mist s) 
oral: ATE = 
1050 mg/kg bw  8 
9’ 
‘611-181-00-6 potassium (oxido -NNO -
azoxy)cyclohexane;  
cyclohexylhydroxydiazene 1 -oxide, 
potassium salt;  
[K-HDO]  - 66603 -10-9 Flam. Sol. 1  
Acute Tox. 3  
STOT RE 2  
Skin Irrit. 2 
Eye Dam. 1  
Aquatic Chronic 
2 H228  
H301  
H373 (liver)  
H315  
H318  
H411  GHS02  
GHS06  
GHS08  
GHS05  
GHS09  
Dgr H228  
H301  
H373 (liver)  
H315  
H318  
H411   oral: ATE = 136 
mg/kg bw ’  
‘612-294-00-3 mecetronium etilsulfate;  
N-ethyl -N,N-dimethylhexadecan -1-
aminium ethyl sulfa te;  
mecetronium ethyl sulphate;  
[MES]  221-106-5 3006 -10-8 Skin Corr. 1  
Eye Dam. 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H314  
H318  
H400  
H410  GHS05  
GHS09  
Dgr H314  
H410  EUH071  M=100  
M=1000 ’  
‘613-331-00-6 (2RS)-2-[4-(4-chlorophenoxy) -2-
(trifluoromethyl)phenyl] -1-(1H-1,2,4 -
triazol -1-yl)propan -2-ol; 
mefentrifluconazole  - 1417782 -03-6 Skin Sens. 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H317  
H400  
H410  GHS07  
GHS09  
Wng  H317  
H410   M=1  
M=1 ’   
EN 10  EN ‘613-332-00-1 oxathiapiprolin (ISO);  
1-(4-{4-[5-(2,6-difluorophenyl) -4,5-
dihydro -1,2-oxazol -3-yl]-1,3-thiazol -2-
yl}piperidin -1-yl)-2-[5-methyl -3-
(trifluoromethyl) -1H-pyrazol -1-
yl]ethanone  - 1003318 -67-9 Aquatic Chronic 
1 H410  GHS09  
Wng  H410   M=1 ’  
‘613-333-00-7 pyrithione zinc; ¶(T-4)-bis[1 -(hydroxy -
.kappa. O)pyridine -2(1H)-thionato -
.kappa. S]zinc  236-671-3 13463 -41-7 Repr. 1B  
Acute Tox. 2  
Acute Tox. 3  
STOT RE 1  
Eye Dam. 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H360D  
H330  
H301  
H372  
H318  
H400  
H410  GHS08  
GHS06  
GHS05  
GHS09  
Dgr H360D  
H330  
H301  
H372  
H318  
H410   inhalation: ATE 
= 0.14 mg/L 
(dust s and 
mists) 
oral: ATE = 221 
mg/kg bw  
M=1000  
M=10 ’  
‘613-334-00-2 flurochloridone  (ISO);  
3-chloro -4-(chloromethyl) -1-[3-
(trifluoromethyl)phenyl]pyrrolidin -2-one 262-661-3 61213 -25-0 Repr. 1B  
Acute Tox. 4  
Skin Sens. 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H360FD  
H302  
H317  
H400  
H410  GHS08  
GHS07  
GHS09  
Dgr H360FD  
H302  
H317  
H410   oral: ATE = 500 
mg/kg bw ¶ 
M=100  
M=100 ’  
‘613-335-00-8 4,5-dichloro -2-octyl -2H-isothiazol -3-one; 
[DCOIT]  264-843-8 64359 -81-5 Acute Tox. 2  
Acute Tox. 4  
Skin Corr. 1  
Eye Dam. 1  
Skin Sens. 1A  
Aquatic Acute 1  
Aquatic Chronic 
1 H330  
H302  
H314  
H318  
H317  
H400  
H410  GHS06  
GHS05  
GHS09  
Dgr H330  
H302  
H314  
H317  
H410  EUH071  inhalation: ATE 
= 0.16 mg/L  
oral: ATE = 567 
mg/kg bw  
Skin Irrit. 2; 
H315: 0,025 % 
≤ C < 5 %  
Eye Irrit. 2; 
H319: 0,025 % 
≤ C < 3 %  
Skin Sens. 1A; 
H317: C ≥ 
0,0015 %  
M=100  
M=100 ’  
‘613-336-00-3 2-methyl -1,2-benzothiazol -3(2H)-one;  
[MBIT]  - 2527 -66-4 Acute Tox. 4  
Acute Tox.  3 
Skin Corr. 1C  
Eye Dam. 1  
Skin Sens. 1A  
Aquatic Acute 1  
Aquatic Chronic 
2 H312  
H301  
H314  
H318  
H317  
H400  
H411  GHS06  
GHS05  
GHS09  
Dgr H312  
H301  
H314  
H317  
H410  EUH071  dermal: ATE = 
1100 mg/kg bw  
oral: ATE = 175 
mg/kg bw  
Skin Sens. 1A; 
H317: C ≥ 
0,0015 %  
M=1 ’   
EN 11  EN  
(b) (b) The entries corresponding to index numbers  007-004-00-1; 014 -018-00-1; 015 -134-00-5; 015 -181-00-1; 050-021-00-4; 050 -
027-00-7; 082 -013-00-1;  082-014-00-7; 603 -014-00-0; 603 -065-00-9; 605-019-00-3; 607 -177-00-9; 607 -256-00-8; 607 -314-00-2; 
609-041-00-4; 609 -064-00-X; 613 -112-00-5; 613 -115-00-1; 613 -125-00-6; 613 -202-00-4; 613 -259-00-5; 616 -014-00-0; 617 -006-
00-X are replaced by the following entries  respectively : 
 ‘616-228-00-4 3-(difluoromethyl) -1-methyl -N-(3',4',5' -
trifluorobiphenyl -2-yl)pyrazole -4-
carboxamide;  
fluxapyroxad  - 907204 -31-3 Lact.  
Aquatic Acute 1  
Aquatic Chronic 
1 H362  
H400  
H410  GHS09  
Wng  H362  
H410   M=1  
M=1 ’  
‘616-230-00-5 N-(hydroxymethyl)acrylamide; 
methylolacrylamide; [NMA]  213-103-2 924-42-5 Carc. 1B  
Muta. 1B  
STOT RE 1  H350  
H340  
H372 
(peripheral 
nervous 
system)  GHS08  
Dgr H350  
H340  
H372 
(peripheral 
nervous 
system) ’    
‘616-231-00-0 5-fluoro -1,3-dimethyl -N-[2-(4-
methylpentan -2-yl)phenyl] -1H-pyrazole -
4-carboxamide; 2’ -[(RS)-1,3-
dimethylbutyl] -5-fluoro -1,3-
dimethylpyrazole -4-carboxanilide;  
penflufen  - 494793 -67-8 Carc. 2  
Aquatic Acute 1  
Aquatic Chronic 
1 H351  
H400  
H410  GHS08  
GHS09  
Wng  H351  
H410   M=1  
M=1 ’  
‘616-232-00-6 iprovalicarb (ISO);  
isopropyl [(2 S)-3-methyl -1-{[1-(4-
methylphenyl)ethyl]amino} -1-oxobutan -
2-yl]carbamate  - 140923 -17-7 Carc. 2  H351  GHS08  
Wng  H351 ’    
‘616-233-00-1 silthiofam (ISO);  
N-allyl-4,5-dimethyl -2-
(trimethylsilyl)thiophene -3-carboxamide  - 175217 -20-6 STOT RE 2  
Aquatic Chronic 
2 H373  
H411  GHS08  
GHS09  
Wng  H373  
H411 ’    
‘650-057-00-6 Margosa, ext. [cold -pressed oil of 
Azadirachta indica  seeds without shells 
extracted with super -critical carbon 
dioxide]  283-644-7 84696 -25-3 Aquatic Chronic 
3 H412   H412 ’     
EN 12  EN Index No  Chemical name  EC No  CAS No  Classification  Labelling  Specific Conc. 
Limits, M -
factors and 
ATE  Notes  
Hazard Class 
and Category 
Code(s)  Hazard 
statement 
Code(s)  Pictogram, 
Signal 
Word   Code(s)  Hazard 
statement 
Code(s)  Suppl. 
Hazard 
statement 
Code(s)  
‘007-004-00-1 nitric acid …% [C > 70 %]  231-714-2 7697 -37-2 Ox. Liq. 2  
Acute Tox. 1  
Skin Corr. 1A  H272  
H330  
H314  GHS03  
GHS06  
GHS05  
Dgr H272  
H330  
H314  EUH071  Ox. Liq. 2; 
H272: C ≥ 99  %  
Ox. Liq. 3; 
H272: 70 % ≤ C 
< 99 % B’ 
‘014-018-00-1 octamethylcyclotetrasiloxane;  
[D4]  209-136-7 556-67-2 Repr. 2  
Aquatic Chronic 
1 H361f ***  
H410  GHS08  
GHS09  
Wng  H361f ***  
H410    
M=10 ’  
‘015-134-00-5 pirimiphos -methyl (ISO);  
O-[2-(diethylamino) -6-methylpyrimidin -4-
yl] O,O-dimethyl phosphorothioate  249-528-5 29232 -93-7 Acute Tox. 4  
STOT RE 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H302  
H372 (nervous 
system)  
H400  
H410  GHS07  
GHS08  
GHS09  
Dgr  H302  
H372 
(nervous 
system)  
H410   oral: ATE = 
1414 mg/kg bw  
 
 
M=1000  
M=1000 ’  
‘015-181-00-1 phosphine  232-260-8 7803 -51-2 Flam. Gas 1  
Press. Gas  
Acute Tox. 1  
Skin Corr. 1B  
Aquatic Acute 1  H220  
H330  
H314  
H400  GHS02  
GHS04  
GHS06  
GHS05  
GHS09  
Dgr H220  
H330  
H314  
H400   inhalation:  
ATE = 10 
ppmV (gases)  U’ 
‘050-021-00-4 dichlorodioctylstannane  222-583-2 3542 -36-7 Repr. 1B  
Acute Tox. 2  
STOT RE 1  
Aquatic Chronic 
3 H360D  
H330  
H372 **  
H412  GHS08  
GHS06  
Dgr H360D  
H330  
H372 **  
H412   Repr. 1B; H360 
D: C ≥ 0,03 %  
inhalation: ATE 
= 0.098 mg/L 
(dust s and 
mists)’  
‘050-027-00-7 2-ethylhexyl 10 -ethyl -4,4-dioctyl -7-oxo-8-
oxa-3,5-dithia -4-stannatetradecanoate; 
[DOTE]  239-622-4 15571 -58-1 Repr. 1B  
STOT RE 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H360D  
H372 (immune 
system)  
H400  
H410  GHS08  
GHS09  
Dgr H360D  
H372 
(immune 
system)  
H410 ‘    
‘082-013-00-1 lead powder; ¶[particle diameter < 1 mm]  231-100-4 7439 -92-1 Repr. 1A  
Lact.  
Aquatic Acute 1  
Aquatic Chronic 
1 H360FD H362  
H400  
H410  GHS08  
GHS09  
Dgr H360FD 
H362  
H410   Repr. 1A; 
H360D: C ≥ 
0,03 %  
M=1  
M=10 ’   
EN 13  EN ‘082-014-00-7 lead massive;  
[particle diameter ≥ 1 mm]  231-100-4 7439 -92-1 Repr. 1A  
Lact.  
Aquatic Acute 1  
Aquatic Chronic 
1 H360FD H362  
H400  
H410  GHS08  
GHS09  
Dgr H360FD 
H362  
H410    
M=1  
M=10 ’  
‘603-014-00-0 2-butoxyethanol;  
ethylene glycol monobutyl ether  203-905-0 111-76-2 Acute Tox. 3  
Acute Tox. 4  
Skin Irrit. 2 
Eye Irrit. 2  H331  
H302  
H315  
H319  GHS06  
Dgr H331  
H302  
H315  
H319   inhalation: ATE 
= 3 mg/L ¶ 
oral: ATE = 
1200 mg/kg 
bw’  
‘603-065-00-9 m-bis(2,3 -epoxypropoxy)benzene;  
resorcinol diglycidyl ether  202-987-5 101-90-6 Carc. 1B ¶ 
Muta. 2 ¶ 
Acute Tox. 3  
Acute Tox. 4  
Skin Irrit. 2  
Eye Irrit. 2  
Skin Sens. 1  
Aquatic Chronic 
3  H350  
H341  
H311  
H302  
H315  
H319  
H317  
H412  GHS08  
GHS06  
Dgr H350  
H341  
H311  
H302  
H315  
H319  
H317  
H412   dermal: ATE = 
300 mg/kg bw 
oral: ATE = 
500 mg/kg bw ¶’  
‘605-019-00-3 citral  226-394-6 5392 -40-5 Skin Irrit. 2  
Skin Sens. 1  H315  
H317  GHS07  
Wng  H315  
H317 ’    
‘607-177-00-9  tribenuron -methyl (ISO);  
methyl 2 -[N-(4-methoxy -6-methyl -1,3,5 -
triazin -2-yl)-N-
methylcarbamoylsulfamoyl]benzoate  401-190-1 101200 -48-0 STOT RE 2  
Skin Sens. 1  
Aquatic Acute 1  
Aquatic Chronic 
1 H373  
H317  
H400  
H410  GHS08  
GHS07 GHS09 
Wng  H373  
H317  
H410   M=100  
M=100 ‘  
‘607-256-00-8 azoxystrobin (ISO);  
methyl ( E)-2-{2-[6-(2-
cyanophenoxy)pyrimidin -4-
yloxy]phenyl} -3-methoxyacrylate  - 131860 -33-8 Acute Tox. 3  
Aquatic Acute 1  
Aquatic Chronic 
1 H331  
H400  
H410  GHS06  
GHS09  
Dgr H331  
H410   inhalation:  
ATE = 0.7 
mg/L (dust and 
mist)  
M=10  
M=10 ’  
‘607-314-00-2 ethofumesate (ISO);  
(RS)-2-ethoxy -2,3-dihydro -3,3-
dimethylbenzofuran -5-yl 
methanesulfonate  247-525-3 26225 -79-6 Aquatic Acute 1  
Aquatic Chronic 
1 H400  
H410  GHS09  
Wng  H410   M=1  
M=1 ‘           
‘609-041-00-4 2,4-dinitrophenol  200-087-7 51-28-5 Acute Tox. 3 *  
Acute Tox. 3  
Acute Tox. 2  
STOT RE 1  
Aquatic Acute 1  H331  
H311  
H300 H372  
H400  GHS06 GHS08 
GHS09  
Dgr  H331  
H311  
H300  
H372  
H400   dermal: ATE = 
300 mg/kg bw 
oral: ATE = 30 
mg/kg bw ’    
EN 14  EN ‘609-064-00-X mesotrione (ISO);  
2-[4-(methylsulfonyl) -2-nitrobenzoyl] -1,3-
cyclohexanedione  - 104206 -82-8 Repr. 2  
STOT RE 2  
Aquatic Acute 1  
Aquatic Chronic 
1 H361d  
H373 (eyes, 
nervous system)  
H400  
H410  GHS08  
GHS09  
Wng  H361d  
H373 (eyes, 
nervous 
system)  
H410   M=10  
M=10 ’   
‘613-112-00-5 octhilinone (ISO);  
2-octyl -2H-isothiazol -3-one; [OIT]  247-761-7 26530 -20-1 Acute Tox. 2  
Acute Tox. 3  
Acute Tox. 3  
Skin Corr. 1  
Eye Dam. 1  
Skin Sens. 1A  
Aquatic Acute 1 
Aquatic Chronic 
1 H330  
H311  
H301  
H314  
H318  
H317  
H400  
H410  GHS06  
GHS05  
GHS09  
Dgr H330  
H311  
H301  
H314  
H317  
H410   inhalation: ATE 
= 0.27 mg/L 
(dust s and 
mists) 
dermal: ATE = 
311 mg/kg bw 
oral: ATE =  
125 mg/kg bw  
Skin Sens. 1; 
H317: C ≥ 
0,0015 %  
M=100  
M=100 ’   
‘613-115-00-1 hymexazol (ISO);  
3-hydroxy -5-methylisoxazole  233-000-6 10004 -44-1 Repr. 2  
Acute Tox. 4  
Eye Dam. 1  
Skin Sens. 1  
Aquatic Chronic 
2 H361d  
H302  
H318  
H317  
H411  GHS08  
GHS07  
GHS05  
GHS09  
Dgr H361d  
H302  
H318  
H317  
H411   oral: ATE = 
1600 mg/kg 
bw’   
‘613-125-00-6 hexythiazox (ISO);  
trans -5-(4-chlorophenyl) -N-cyclohexyl -4-
methyl -2-oxo-3-thiazolidine -carboxamide  - 78587 -05-0 Aquatic Acute 1  
Aquatic Chronic 
1 H400  
H410  GHS09  
Wng  H410   M=1  
M=1 ’   
‘613-202-00-4 pymetrozine (ISO);  
(E)-4,5-dihydro -6-methyl -4-(3-
pyridylmethyleneamino) -1,2,4 -triazin -
3(2H)-one - 123312 -89-0 Carc. 2    
Repr. 2  
Aquatic Chronic 
1 H351  
H361fd  
H410  GHS08  
GHS09  
Wng  H351  
H361fd  
H410   M=1 ’ 
  
‘613-259-00-5 imiprothrin (ISO);  
reaction mass of: [2,4 -dioxo -(2-propyn -1-
yl)imidazolidin -3-yl]methyl(1 R)-cis-
chrysanthemate; [2,4 -dioxo -(2-propyn -1-
yl)imidazolidin -3-yl]methyl(1 R)-trans -
chrysanthemate  428-790-6 72963 -72-5 Carc. 2  
Acute Tox. 4  
Acute Tox. 4  
STOT SE 2  
Aquatic Acute 1  
Aquatic Chronic 
1 H351  
H332  
H302  
H371 (nervous 
system; oral, 
inhalation) ¶H40
0 
H410  GHS08  
GHS07  
GHS09  
Wng  H351  
H332  
H302  
H371 
(nervous 
system; oral, 
inhalation)  
H410   inhalation: ATE 
= 1.4 mg/L 
(dust s and 
mists) 
oral: ATE = 
550 mg/kg bw  
 
M=10  
M=10 ‘    
EN 15  EN ‘616-014-00-0 butanone oxime; ¶ethyl methyl ketoxime; 
¶ethyl methyl ketone oxime  202-496-6 96-29-7 Carc. 1B  
Acute Tox. 4  
Acute Tox. 3  
STOT SE 3  
STOT SE 1  
STOT RE 2  
Skin Irrit. 2 
Eye Dam. 1  
Skin Sens. 1 ¶ H350  
H312  
H301  
H336  
H370 (upper 
respiratory 
tract)H373 
(blood system)  
H315  
H318  
H317 ¶ GHS08  
GHS06 ¶ 
GHS05  
Dgr H350  
H312 ¶ 
H301  
H336  
H370 (upper 
respiratory 
tract) ¶H373 
(blood 
system)  
H315  
H318  
H317   dermal: ATE = 
1100 mg/kg bw 
oral: ATE = 
100 mg/kg bw ’   
 
‘617-006-00-X bis(α,α -dimethylbenzyl) peroxide  201-279-3 80-43-3 Org. Perox. F 
Repr. 1B  
Skin Irrit. 2 
Eye Irrit. 2  
Aquatic Chronic 
2 H242  
H360D  
H315  
H319  
H411  GHS02  
GHS08  
GHS07  
GHS09  
Dgr H242  
H360D ¶ 
H315  
H319  
H411 ’   
  
 
(c) the entries corresponding to index numbers 601-064-00-8 and 607 -693-00-4 are deleted . 
 
 
 